ReviewBioelectronic medicine2018
Automated closed-loop control of diabetes: the artificial pancreas.
Review in Bioelectronic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 75 citations in OpenAlex.
- Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes.Diabetes technology & therapeutics · 2022Trial
- Randomized Controlled Trial of Mobile Closed-Loop Control.Diabetes care · 2020Trial
- Clinical and metabolic outcomes of artificial pancreas systems in patients with type 1 diabetes: A real-world study.The International journal of artificial organs · 2026Article
- Artificial Intelligence for Blood Glucose Level Prediction in Type 1 Diabetes: Methods, Evaluation, and Emerging Advances.Sensors (Basel, Switzerland) · 2026Review
- Editorial: Technologies for diabetes, volume III.Frontiers in endocrinology · 2026Article
- An Ethical Framework for Addressing the Differential Impact of Systemic Racism and Inequities on Type 1 and Type 2 Diabetes Mellitus in Youth in the United States.Hormone research in paediatrics · 2025Review
- Adaptive average arterial pressure control by multi-agent on-policy reinforcement learning.Scientific reports · 2025Article
- Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease.Advanced drug delivery reviews · 2024Review
- A Glucose-Responsive Cannula for Automated and Electronics-Free Insulin Delivery.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?International journal of molecular sciences · 2023Review
- New model of glucose-insulin regulation characterizes effects of physical activity and facilitates personalized treatment evaluation in children and adults with type 1 diabetes.PLoS computational biology · 2023Article
- A system theory based digital model for predicting the cumulative fluid balance course in intensive care patients.Frontiers in physiology · 2023Article
- Effectiveness and safety of a model predictive control (MPC) algorithm for an artificial pancreas system in outpatients with type 1 diabetes (T1D): systematic review and meta-analysis.Diabetology & metabolic syndrome · 2022Review
- Review
- Examining Type 1 Diabetes Mathematical Models Using Experimental Data.International journal of environmental research and public health · 2022Article
- The Evolution of Insulin Administration in Type 1 Diabetes.Journal of diabetes mellitus · 2021Article
- Powering Implantable and Ingestible Electronics.Advanced functional materials · 2021Article
- Intelligent automated drug administration and therapy: future of healthcare.Drug delivery and translational research · 2021Review
- Mechanistic Computational Models of Epithelial Cell Transporters-the Adorned Heroes of Pharmacokinetics.Frontiers in pharmacology · 2021Review
- Inflammation neuroscience: neuro-immune crosstalk and interfaces.Clinical & translational immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of Diabetes Mellitus is on the rise worldwide, which exerts enormous health toll on the population and enormous pressure on the healthcare systems. Now, almost hundred years after the discovery of insulin in 1921, the optimization problem of diabetes is well formulated as maintenance of strict glycemic control without increasing the risk for hypoglycemia. External insulin administration is mandatory for people with type 1 diabetes; various medications, as well as basal and prandial insulin, are included in the daily treatment of type 2 diabetes. This review follows the development of the Diabetes Technology field which, since the 1970s, progressed remarkably through continuous subcutaneous insulin infusion (CSII), mathematical models and computer simulation of the human metabolic system, real-time continuous glucose monitoring (CGM), and control algorithms driving closed-loop control systems known as the "artificial pancreas" (AP). All of these developments included significant engineering advances and substantial bioelectronics progress in the sensing of blood glucose levels, insulin delivery, and control design. The key technologies that enabled contemporary AP systems are CSII and CGM, both of which became available and sufficiently portable in the beginning of this century. This powered the quest for wearable home-use AP, which is now under way with prototypes tested in outpatient studies during the past 6 years. Pivotal trials of new AP technologies are ongoing, and the first hybrid closed-loop system has been approved by the FDA for clinical use. Thus, the closed-loop AP is well on its way to become the digital-age treatment of diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.